A phase I/II study with single-agent midostaurin (PKC412) in children with r/r acute leukemia including KMT2A-rearranged ALL and FLT3-mutated AML was terminated early due to insufficient recruitment (NCT00866281). The gene discussed is FLT3; the disease is acute myeloid leukemia.